



# Corrigendum: When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

Kaleen N. Hayes<sup>1</sup>, Ulrike Baschant<sup>2\*</sup>, Barbara Hauser<sup>3,4</sup>, Andrea M. Burden<sup>5</sup> and Elizabeth M. Winter<sup>6</sup>

<sup>1</sup> Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, RI, United States, <sup>2</sup> Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany, <sup>3</sup> Rheumatic Disease Unit, Western General Hospital, National Health Service (NHS) Lothian, Edinburgh, United Kingdom, <sup>4</sup> Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom, <sup>5</sup> Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology [Eidgenössische Technische Hochschule (ETH)] Zurich, Zurich, Switzerland, <sup>6</sup> Center for Bone Quality, Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, Netherlands

## OPEN ACCESS

### Approved by:

Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

### \*Correspondence:

Ulrike Baschant  
Ulrike.Baschant@uniklinikum-  
dresden.de

### Specialty section:

This article was submitted to  
Bone Research,  
a section of the journal  
Frontiers in Endocrinology

**Received:** 16 February 2022

**Accepted:** 23 February 2022

**Published:** 14 March 2022

### Citation:

Hayes KN, Baschant U, Hauser B,  
Burden AM and Winter EM (2022)  
Corrigendum: When to Start  
and Stop Bone-Protecting  
Medication for Preventing  
Glucocorticoid-Induced Osteoporosis.  
*Front. Endocrinol.* 13:877512.  
doi: 10.3389/fendo.2022.877512

**Keywords:** glucocorticoid-induced osteoporosis, glucocorticoids, bone fractures, bone density, anti-resorptive treatment, bone density conservation agents, bisphosphonates, teriparatide

## A Corrigendum on

### When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis

by Hayes KN, Baschant U, Hauser B, Burden AM and Winter EM (2021). *Front. Endocrinol.* 12:782118. doi: 10.3389/fendo.2021.782118

In the article as published originally, Elizabeth M. Winter was erroneously presented as the corresponding author instead of Ulrike Baschant.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Hayes, Baschant, Hauser, Burden and Winter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.